Iberdomide (NCT06107738)

Name: Iberdomide trial for Multiple Myeloma (NCT06107738)
Uploaded: 2026-10-31T22:47:47.873Z
Duration: 1 min 12 s
Description: Iberdomide trial for Multiple Myeloma (NCT06107738). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06107738.

Iberdomide and Daratumumab as Maintenance Therapy After an Autologous Stem Cell Transplant for Multiple Myeloma: a one-minute explainerNCT061077381 min

Iberdomide trial for Multiple Myeloma (NCT06107738). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

What the film says

Read the transcript

This trial is for adults with myeloma and residual disease after autologous transplant, following response to daratumumab-based induction. Transplant must have occurred ninety to one hundred fifty days earlier.

The idea: oral iberdomide promotes breakdown of proteins involved in myeloma growth and immune regulation. Daratumumab injections target CD38. Treatment can last twenty-six four-week cycles. Bone-marrow testing tracks residual disease, including whether it becomes undetectable at twelve months. Prior daratumumab intolerance excludes participation.

This phase 2 study plans 60 patients. Jeffrey Zonder leads at Karmanos, Detroit; two US sites recruit.

Public record; not medical advice.

Read the full brief →

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.